Novel immunotherapy drugs are used to treat advanced bladder cancer when chemotherapy is no longer working. However, only one in five patients responds to immunotherapy, likely due to biological differences in bladder cancer. Join Dr. Andreev-Drakhlin recipient of The ASCO Foundation 2020 Conquer Cancer Young Investigator Award as he presents his research plans in using fibroblast growth factor receptor (FGFR) inhibitors for improving the effectiveness of immunotherapy for bladder cancer.
Dr. Andreev-Drakhlin is a medical oncology fellow in the Physician-Scientist track at the University of Texas, M.D. Anderson Cancer Center. Born and raised in St. Petersburg, Russia, he attended St. Petersburg State University, where Dr. Andreev-Drakhlin obtained his medical degree with Highest Distinction. Following his graduation, he pursued further scientific training at the laboratory of Levi Garraway at the Broad Institute of Harvard and MIT. There he was involved in several cutting-edge genomics projects, which included single-cell sequencing, deep mutational scanning, as well as creating novel genetic screening tools. The results of his work contributed to publications in Nature, Science, and Cell Reports. He was subsequently recruited to the International Scholars Track within the internal medicine residency program at the University of Pittsburgh. There, in addition to acquiring traditional clinical expertise, he completed master’s level course work at the University of Pittsburgh Institute for Clinical Research Education. In 2018, Dr. Andreev-Drakhlin was accepted into the hematology/oncology fellowship training program at the University of Texas MD Anderson Cancer Center, where he currently serves as a T32 fellow. Dr. Andreev-Drakhlin's current research efforts are focused on improving the outcomes for patients with advanced FGFR3-mutated urothelial cancer. Upon completion of his fellowship, Dr. Andreev-Drakhlin intends to pursue an academic translational career in drug development with the focus on studying the mechanisms of drug resistance in order to design effective therapeutic combinations.
The Texas Society of Clinical Oncology (TxSCO) is a Chapter Member of the Association of Community Cancer Centers (ACCC). TxSCO members receive access to valuable educational content and targeted resources through ACCC to support their professional development.
· The ACCC Immuno-Oncology Institute is the leader in optimizing the delivery of cancer immunotherapies for patients by providing clinical education, advocacy, research, and practice management solutions for multidisciplinary cancer care teams across all healthcare settings.
· The ACCC COVID-19 Resource Center contains webcasts, podcasts, and blogs, and resources on the pandemic from federal and professional organizations.
· The ACCC COVID-19 Financial Advocacy Resources Hub features new and updated foundation assistance, updates to manufacturer assistance programs, and Medicare and Medicaid coverage updates.
· TxSCO members can connect in real-time through members-only virtual discussion forum on ACCCeXchange. Within this forum, TxSCO members from every profession involved in cancer care delivery ask and answer questions, discuss common challenges, and share knowledge and experience. Join the discussion and connect with your peers.
· Tap into the value of TxSCO membership! Visit our membership page for more information on how you can join our community of professionals. If you’re unsure of your membership status, please contact our membership department today.
· The ACCCeLearning portal makes it easy to find education relevant to your needs and interests. Accessible on any device and at any time, courses are available in a variety of formats, so you can listen, watch, read or interact in ways that best suit your needs. Health professionals can claim CME/CPE/CNE credit for all applicable activities. Since you’re already logged in, take a look around today!